Leonard Guarent, a professor from MIT, conducted a study combining nicotinamide riboside (NR) with pterostilbene. The results indicate that this combination can lower inflammatory markers in individuals suffering from non-alcoholic fatty liver disease (NAFLD). Individuals with NAFLD who consumed a mixture of pterostilbene and nicotinamide riboside (NRPT) experienced decreased levels of inflammatory liver enzymes. NRPT effectively lowered the presence of ceramide 14:0, a harmful lipid that causes liver disease in humans. These positive results were observed only when participants adhered to the recommended daily dosage. Individuals who took twice the recommended amount did not get to experience the same benefits. Non-alcoholic fatty liver disease (NAFLD) is a terrible disease affecting many around the globe. The condition has a staggering prevalence of 30% worldwide. And that’s not all! Nearly 2 million people lose their battle against NAFLD each year globally. NAFLD is marked by the accumulation of fat and inflammation in the liver. The disease is a grim reality for many. However, a ray of hope has emerged in the form of a recent study. Researchers have explored the potential of combining NAD+-boosting nicotinamide riboside (NR) and pterostilbene to combat the pervasive health issue. Guarente and his team at Elysium Health conducted a meticulous study on the effects of NRPT. The results of their research were published in Hepatology. The study takes a significant step forward in understanding how NAFLD can be mitigated effectively. The focus of the researchers was the synergy between nicotinamide riboside supplement, a compound known to increase nicotinamide adenine dinucleotide (NAD+) levels, and pterostilbene, a sirtuin-activating compound (STAC). Sirtuins, pro-longevity proteins, have been identified as key players in countering NAFLD. Testing The NR- Pterostilbene Combination The researchers aimed to measure the impact of the nicotinamide riboside supplement and pterostilbene combination (NRPT) on liver enzymes linked with inflammation. To do this, the team examined 111 patients of NAFLD over a period of 90 as well as 180 days. The outcomes were quite striking. Patients who stuck to the recommended daily dosage for 180 days experienced a significant reduction in gamma-glutamyltransferase and alanine transaminase levels. Both these enzymes are markers indicating inflammation in the body. The reduction in their levels highlighted the potential of the NRPT combo in alleviating liver inflammation in NAFLD patients. Ceramide Reducing Impact of NRPT In Nicotinamide Riboside Clinical Trial A crucial finding in the study was the effect of NRPT on ceramide 14:0, a harmful lipid that’s known to exacerbate NAFLD. After taking the supplementation for six months, patients following the recommended NRPT dosage exhibited a substantial decrease in levels of ceramide 14:0. On the contrary, patients who exceeded the daily dosage by taking twice the recommended amount did not witness the same benefits. Thus, the results indicate that taking the correct dose of NRPT is necessary for the compound to work efficiently. Nicotinamide Riboside Liver Benefits are Dose-Specific Digging deeper, the researchers studied the underlying mechanisms of the NRPT combination. This offered the team insights into why the dosage played such a pivotal role. What they discovered is that excessive intake of NR might convert to nicotinamide. This inhibits sirtuin activity—a crucial factor in combating NAFLD. Similarly, an overdose of pterostilbene can exceed its optimum efficacy, making the sirtuin activator ineffective. Nicotinamide Riboside Supplement Study Shortcomings While the study presented encouraging results, some questions still lingered. Not all measured liver enzymes exhibited a significant reduction. This shortfall raises concerns about the consistency of the findings. To support the credibility of the anti-inflammatory effects of NRPT, future studies need to involve larger participant groups. The researchers also need to extend the clinical trial period of the studies. Hence, using a comprehensive approach will provide a wholesome understanding of the supplement combination’s potential to address liver inflammation. NR Research Future Outcomes During the nicotinamide riboside human trials, the NRPT combination became a symbol of hope for those dealing with NAFLD. By adhering to the recommended dosage, individuals could potentially find relief from liver inflammation, improving their quality of life significantly. The study opens new avenues for further research. It also offers a promising solution to the pressing issue of NAFLD. This treatment can potentially transform the lives of millions affected by the prevalent condition. As scientific exploration continues, the synergistic power of NR and pterostilbene will continue to be uncovered. It might even give rise to a new era in NAFLD treatment, providing a brighter future for patients worldwide.